BIO-Europe Spring Presenting Companies 2023
Mursla (Cambridge, UK) is an emergent techbio startup, leveraging extracellular vesicle biology to deliver nextgen multi-omics liquid biopsy tests.
Its first product is a blood test to significantly improve the early detection of liver cancer among high-risk populations so that more patients can benefit from curative treatments (surgery/transplant).
Its test is first-in-class and is differentiated from first generation liquid biopsy blood tests using circulating free DNA since it is tissue-specific, multi-omics and offers real time snapshot of disease biology.
Mursla was selected as UK Life Sciences Innovator 2023 in the Diagnostics and Precision Medicine category.